Lv1
56 积分 2022-09-03 加入
OA08.04 Primary Endpoint Results from SHERLOCK: a Phase 2 trial of Sotorasib, Bevacizumab and Chemotherapy in Advanced KRAS G12C NSCLC
3个月前
已关闭
AGER-dependent macropinocytosis drives resistance to KRAS-G12D–targeted therapy in advanced pancreatic cancer
4个月前
已完结
Establishment of Pancreatic Cancer-Derived Tumor Organoids and Fibroblasts From Fresh Tissue
4个月前
已完结
Enhancing the Efficacy of Glutamine Metabolism Inhibitors in Cancer Therapy
4个月前
已完结
Associations between metabolites and pancreatic cancer risk in a large prospective epidemiological study
4个月前
已完结
Comparative genomic landscape of acquired resistance in pancreatic cancer treated with pan-RAS or KRASG12C inhibitors
5个月前
已关闭
Data from Scavenger Receptor CD36 in Tumor-Associated Macrophages Promotes Cancer Progression by Dampening Type-I IFN Signaling
7个月前
已完结
皖公网安备34019202002308
